title: High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin.
abstract: BACKGROUND
  There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen.
  
  
  METHODS
  Based on the results of a previously published phase II study, we associated the (99m)Technetium-labelled liposomal doxorubicin ((99m)Tc-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin.
  
  
  RESULTS
  Patients with tumours exhibiting increased (99m)Tc-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % (p < 0.001); 6.9 versus 3.2 months (p = 0.033) and 23 versus 6.6 months (p = 0.001), respectively.
  
  
  CONCLUSIONS
  (99m)Tc-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen.
authors.affiliation: Thoracic Oncology Unit, Instituto Nacional de Cancerología, San Fernando # 22, Col. Sección XVI, Tlalpan, Mexico City, C.P. 14080, Mexico, ogar@unam.mx.
authors.forename: Oscar
authors.initials: O
authors.lastname: Arrieta
authors.forename: Luis-Alberto
authors.initials: LA
authors.lastname: Medina
authors.forename: Enrique
authors.initials: E
authors.lastname: Estrada-Lobato
authors.forename: Laura-Alejandra
authors.initials: LA
authors.lastname: Ramírez-Tirado
authors.forename: Víctor-Osvaldo
authors.initials: VO
authors.lastname: Mendoza-García
authors.forename: Jaime
authors.initials: J
authors.lastname: de la Garza-Salazar
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015415:Biomarkers; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008081:Liposomes; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D014677:Pharmaceutical Vehicles; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D019275:Radiopharmaceuticals; D016019:Survival Analysis; D013667:Technetium; D014018:Tissue Distribution; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D008081:Liposomes; D014677:Pharmaceutical Vehicles; D019275:Radiopharmaceuticals; D013667:Technetium; D004317:Doxorubicin; D002945:Cisplatin